European DataWarehouse Presents 4 th Annual Data Quality Award
European DataWarehouse (EDW) presented its fourth annual Data Quality Award yesterday at the 2025 TSI Congress in Berlin.
This year EDW presented the annual Best Data Quality – Deal of the Year (2024-2025) award to CaixaBank SA and CaixaBank Titulización SGFT, SAU for their deal, CAIXABANK PYMES 13, F.T.
“We are delighted to be recognized with the ‘Best Data Quality – Deal of the Year’ award from European DataWarehouse. Our focus on precision and reliability in reporting is strengthened by EDW’s solutions, which help us consistently meet the highest standards,” said Álvaro Hernández Martínez, Director of Credit Risk Policies and Information at CaixaBank SA.
The award program was founded in 2022 and was first presented at EDW’s 10th anniversary celebration in Frankfurt. The award program recognizes exceptional effort and superior data quality from ABS issuers and their servicers.
While presenting the award EDW’s CEO, Dr. Christian Thun, remarked, “EDW’s award program highlights the importance of high-quality data and allows us to acknowledge the outstanding commitment of our issuers. Their careful work ensures that data remains trustworthy and impactful for risk assessment, investment decisions, and research.”
Award recipients are selected using an overall data-quality score based on thousands of data rules and checks developed by European DataWarehouse.
EDW identified a need to introduce data quality scoring on a deal level to easily communicate data quality and monitor its improvements as early as 2016. Since then, EDW has developed and applied more than 4,000 rules and checks to both the ECB Loan-Level Data templates and the ESMA Underlying Exposures, Investor Report, and Significant Event templates.
About European DataWarehouse
European DataWarehouse (EDW) is a designated Securitisation Repository, authorised by both the European Securities and Markets Authority (ESMA) and the UK’s Financial Conduct Authority (FCA). Established in 2012, EDW was the first repository of its kind in Europe, created to improve transparency and support due diligence in the asset-backed securities (ABS) market.
EDW collects, validates, and provides access to standardised loan-level data and related documentation for ABS transactions and private whole loan portfolios. By serving as a central data hub, EDW enables investors, issuers, and regulators to efficiently analyse and compare portfolios, fostering greater trust and efficiency in the securitisation ecosystem.
To learn more or stay up to date with our latest insights and developments, visit www.eurodw.eu / www.eurodw.co.uk or follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251009328104/en/
Contacts
Media Contact:
European DataWarehouse GmbH
Diane Vogelpohl
Marketing & Communications Manager
Tel. 49 (0) 69 50986 9326
Email: diane.vogelpohl@eurodw.eu
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press Release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press Release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press Release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press Release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom